NOAH has welcomed the publication on 25 July of the House of Lords European Union Committee report ‘Brexit: Farm Animal Welfare’.

Comment from NOAH on the House of Lords European Union Committee ‘Brexit: Farm Animal Welfare’ report

NOAH has welcomed the publication on 25 July of the House of Lords European Union Committee report ‘Brexit: Farm Animal Welfare’.

NOAH Chief Executive Dawn Howard says; “As stated in the report the industry is united in supporting high standards of animal welfare post-Brexit. Good animal health is integral to good welfare, and we support the Report’s acknowledgement that the veterinary profession is integral to the welfare role. Our sector provides tools such as vaccines to help the veterinary profession prevent disease and suffering, and medicines to treat where needed.

“In NOAH’s own first Brexit Barometer, also published yesterday, the animal medicines sector has shown optimism about the future for UK animal health and welfare post-Brexit, despite a degree of uncertainly overall. We look forward to working with those involved in the political process to help
ensure this optimism is realised.”

To download the full report, click here. The next Brexit Barometer will be launched following NOAH’s Brexit Conference in November 2017.

Notes to editors

For further information please contact Alison Glennon or Dawn Howard at NOAH 020 8367 3131 or email a.glennon@noah.co.uk.

About NOAH
1. NOAH represents the UK animal medicines industry. Its aim is to promote the benefits of safe, effective, quality medicines for the health and welfare of all animals. For further information, please visit: www.noah.co.uk

2. NOAH’s Brexit Barometer is available on the NOAH website.

3. To deliver a thriving animal medicines sector, post-Brexit, NOAH has set out a series of priorities that will:
– Support trade and innovation
– Safeguard animal health and welfare and public health and food safety; ensuring that UK veterinarians and animal keepers continue to have access to a wide range of appropriate veterinary medicines.
– Ensure businesses have access to skilled staff – the right workforce they need.
– Incentivise product research and development within a regulatory system which continues to be one of the most stringent in the world – making UK the first choice world-leading regulatory authority.
– Encourage companies to do business in the UK as unnecessary regulatory burdens are recognised and removed.
– Ensure transitional arrangements to support business continuity post EU Exit are built, utilising links with
specialist EU infrastructure where necessary.